Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity

• DOI: 10.1002/adma.201703969
• Publication Date: 2017-11-02T07:18:49Z
• Authors: Ashley V. Kroll; Ronnie H. Fang; Yao Jiang; Jiarong Zhou; Xiaoli Wei; Chun Lai Yu; Jie Gao; Brian T. Luk; Diana Dehaini; Weiwei Gao; Liangfang Zhang
• Keywords: Immunoadjuvant; Cancer vaccine; Immunopotentiator

Anticancer vaccines train the body's own immune system to recognize and eliminate malignant cells based on differential antigen expression. While conceptually attractive, clinical efficacy is lacking given several key challenges stemming from similarities between cancerous healthy tissue. Ideally, an effective vaccine formulation would deliver multiple tumor antigens in a fashion that potently stimulates endogenous responses against those antigens. Here, it reported fabrication of biomimetic, nanoparticulate anticancer capable delivering autologously derived material together with highly immunostimulatory adjuvant. The two major components, adjuvant, are presented concurrently maximizes their ability promote presentation activation downstream processes. Ultimately, demonstrated can elicit potent antitumor vivo. When combined additional immunotherapies such as checkpoint blockades, nanovaccine demonstrates substantial therapeutic effect. Overall, work represents rational application nanotechnology for immunoengineering provide blueprint future development personalized, autologous broad applicability.